Literature DB >> 17072839

Distribution of MT1 melatonin receptor immunoreactivity in the human hypothalamus and pituitary gland: colocalization of MT1 with vasopressin, oxytocin, and corticotropin-releasing hormone.

Ying-Hui Wu1, Jiang-Ning Zhou, Rawien Balesar, Unga Unmehopa, Aimin Bao, Ralf Jockers, Joop Van Heerikhuize, Dick F Swaab.   

Abstract

Melatonin is implicated in numerous physiological processes, including circadian rhythms, stress, and reproduction, many of which are mediated by the hypothalamus and pituitary. The physiological actions of melatonin are mainly mediated by melatonin receptors. We here describe the distribution of the melatonin receptor MT1 in the human hypothalamus and pituitary by immunocytochemistry. MT1 immunoreactivity showed a widespread pattern in the hypothalamus. In addition to the area of the suprachiasmatic nucleus (SCN), a number of novel sites, including the paraventricular nucleus (PVN), periventricular nucleus, supraoptic nucleus (SON), sexually dimorphic nucleus, the diagonal band of Broca, the nucleus basalis of Meynert, infundibular nucleus, ventromedial and dorsomedial nucleus, tuberomamillary nucleus, mamillary body, and paraventricular thalamic nucleus were observed to have neuronal MT1 receptor expression. No staining was observed in the nucleus tuberalis lateralis and bed nucleus of the stria terminalis. The MT1 receptor was colocalized with some vasopressin (AVP) neurons in the SCN, colocalized with some parvocellular and magnocellular AVP and oxytocine (OXT) neurons in the PVN and SON, and colocalized with some parvocellular corticotropin-releasing hormone (CRH) neurons in the PVN. In the pituitary, strong MT1 expression was observed in the pars tuberalis, while a weak staining was found in the posterior and anterior pituitary. These findings provide a neurobiological basis for the participation of melatonin in the regulation of various hypothalamic and pituitary functions. The colocalization of MT1 and CRH suggests that melatonin might directly modulate the hypothalamus-pituitary-adrenal axis in the PVN, which may have implications for stress conditions such as depression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072839     DOI: 10.1002/cne.21152

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  34 in total

Review 1.  Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes.

Authors:  Seithikurippu R Pandi-Perumal; Ahmed S BaHammam; Gregory M Brown; D Warren Spence; Vijay K Bharti; Charanjit Kaur; Rüdiger Hardeland; Daniel P Cardinali
Journal:  Neurotox Res       Date:  2012-06-28       Impact factor: 3.911

2.  Melatonin regulates somatotrope and lactotrope function through common and distinct signaling pathways in cultured primary pituitary cells from female primates.

Authors:  Alejandro Ibáñez-Costa; José Córdoba-Chacón; Manuel D Gahete; Rhonda D Kineman; Justo P Castaño; Raúl M Luque
Journal:  Endocrinology       Date:  2014-12-29       Impact factor: 4.736

Review 3.  Melatonin in Alzheimer's Disease: A Latent Endogenous Regulator of Neurogenesis to Mitigate Alzheimer's Neuropathology.

Authors:  Md Farhad Hossain; Md Sahab Uddin; G M Sala Uddin; Dewan Md Sumsuzzman; Md Siddiqul Islam; George E Barreto; Bijo Mathew; Ghulam Md Ashraf
Journal:  Mol Neurobiol       Date:  2019-06-17       Impact factor: 5.590

4.  12-year-old boy with a 4q35.2 microdeletion and involvement of MTNR1A, FAT1, and F11 genes.

Authors:  Erin L Youngs; Rebecca S Henkhaus; Jessica A Hellings; Merlin G Butler
Journal:  Clin Dysmorphol       Date:  2012-04       Impact factor: 0.816

5.  Microtubules modulate melatonin receptors involved in phase-shifting circadian activity rhythms: in vitro and in vivo evidence.

Authors:  Michael J Jarzynka; Deepshikha K Passey; David A Johnson; Nagarjun V Konduru; Nicholas F Fitz; Nicholas M Radio; Mark Rasenick; Susan Benloucif; Melissa A Melan; Paula A Witt-Enderby
Journal:  J Pineal Res       Date:  2008-10-28       Impact factor: 13.007

Review 6.  Effects of circadian disruption on the cardiometabolic system.

Authors:  Melanie Rüger; Frank A J L Scheer
Journal:  Rev Endocr Metab Disord       Date:  2009-12       Impact factor: 6.514

7.  Suprachiasmatic nucleus neuropeptide expression in patients with Huntington's Disease.

Authors:  Daniel J van Wamelen; N Ahmad Aziz; Jasper J Anink; Robin van Steenhoven; Debora Angeloni; Franco Fraschini; Ralf Jockers; Raymund A C Roos; Dick F Swaab
Journal:  Sleep       Date:  2013-01-01       Impact factor: 5.849

8.  Melatonin signaling in mouse cerebellar granule cells with variable native MT1 and MT2 melatonin receptors.

Authors:  Marta Imbesi; Tolga Uz; Svetlana Dzitoyeva; Pietro Giusti; Hari Manev
Journal:  Brain Res       Date:  2008-06-28       Impact factor: 3.252

9.  Role of melatonin receptors in the effects of melatonin on BDNF and neuroprotection in mouse cerebellar neurons.

Authors:  Marta Imbesi; Tolga Uz; Hari Manev
Journal:  J Neural Transm (Vienna)       Date:  2008-05-21       Impact factor: 3.575

10.  The end of a myth: cloning and characterization of the ovine melatonin MT(2) receptor.

Authors:  F Cogé; S P Guenin; I Fery; M Migaud; S Devavry; C Slugocki; C Legros; C Ouvry; W Cohen; N Renault; O Nosjean; B Malpaux; P Delagrange; J A Boutin
Journal:  Br J Pharmacol       Date:  2009-10-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.